Skip to main content
. Author manuscript; available in PMC: 2020 Jul 15.
Published in final edited form as: Clin Cancer Res. 2019 Oct 21;26(2):408–418. doi: 10.1158/1078-0432.CCR-18-4147

Figure 2. Syringotropic tumoral nodule resistant to topical, light and systemic therapies completely responds to 4 Gray (Gy) x2 radiation with long-term durable response with >99% reduction of malignant T cell burden.

Figure 2.

(A) Photo of tumoral nodule and plaques on left plantar foot prior to LDRT and (B) 6 years after LDRT showing residual biopsy scar but continued remission at site of therapy. (C) 3D histogram of the TCRB sequencing data shows V and J gene expression of hyperexpanded malignant T cell clone with resultant nucleotide and translated amino acid (AA) sequence of the CDR3 region. Based on productive templates, HTS revealed a malignant clone frequency of 81% and 8,181 malignant T cells/100ng DNA. (D) 3D histogram of the TCRB sequencing data shows a polyclonal population of benign T cells with a drastic reduction of the original tumor clone frequency to 0.14% and after normalization of sequencing data, the equivalent of 0.3 residual malignant T cells/100ng DNA (orange arrow).